5-HT1A receptor agonists(Serotonin 1a (5-HT1a) receptor agonists), 5-HT2A receptor antagonists(Serotonin 2a (5-HT2a) receptor antagonists), D4 receptor antagonists(Dopamine D4 receptor antagonists)

Therapeutic Areas

Other Diseases

Active Indication

Sexual Dysfunctions, PsychologicalDecreased libido

Inactive Indication

Depressive Disorder

Originator Organization

Sprout Pharmaceuticals, Inc.

Active Organization

Valeant Canada S.E.C./Valeant Canada LP

Sprout Pharmaceuticals, Inc.

Inactive Organization-

License Organization

Bausch Health Cos., Inc.

Sprout Pharmaceuticals, Inc.

Searchlight Pharma, Inc.

Drug Highest PhaseApproved

First Approval Date

United States (18 Aug 2015),

Sexual Dysfunctions, Psychological

RegulationPriority Review (United States)

Structure/Sequence

Molecular FormulaC20H21F3N4O

InChIKeyPPRRDFIXUUSXRA-UHFFFAOYSA-N

CAS Registry167933-07-5

Clinical Trials associated with Flibanserin

NCT04743934

/ Active, not recruitingPhase 2IIT

RAD 2003/XUAB2104: Randomized Phase II Trial of Flibanserin in Men Receiving Androgen Suppression for Prostate Cancer

This is a double-blinded, placebo-controlled randomized phase II clinical trial investigating whether flibanserin promotes sexual interest in men with prostate cancer who are receiving androgen suppression.

Start Date02 Jul 2021

Sponsor / Collaborator

The University of Alabama at Birmingham

[+1]

NCT04002661

/ TerminatedPhase 2IIT

Hypoactive Sexual Desire Disorder in Males (10-18-40-13)

The purpose of this study is to determine if the study drug will increase sexual desire in men with HSDD. Half of the participants will take ADDYI while the other half will receive a placebo (a look-alike pill with no medicine).

Start Date08 May 2020

Sponsor / Collaborator

Baylor College of Medicine

[+1]

NCT04494191

/ CompletedPhase 1

Comparative Randomized, Single Dose, Two-way Crossover Open-label Study to Determine the Bioequivalence of Flibanserin From AphroFemine 100 mg F.C.T (Bio Med for Pharmaceuticals Industries (BIOMED), Egypt) Versus Addyi 100 mg Tablets (Sprout Pharmaceuticals, Inc., USA)

An open label randomized, single dose, two-way crossover bioequivalence study to determine the bioequivalence of Flibanserin From AphroFemine 100 mg F.C.T (Bio Med for Pharmaceuticals Industries (BIOMED), Egypt) Versus Addyi 100 mg Tablets (Sprout Pharmaceuticals, Inc., USA)

Start Date12 Dec 2018

Sponsor / Collaborator

Genuine Research Center - Grc

[+1]

100 Clinical Results associated with Flibanserin

100 Translational Medicine associated with Flibanserin

100 Patents (Medical) associated with Flibanserin

210

Literatures (Medical) associated with Flibanserin

01 Jan 2026·BIOMEDICAL CHROMATOGRAPHY

Development of Spraying Based Liquid Phase Microextraction Method for the Preconcentration of Flibanserin From Urine Samples via GC–MS Analyses

Article

Author: Kasa, Nursu Aylin ; Bakırdere, Sezgin ; Bodur, Süleyman ; Zaman, Buse Tuğba

ABSTRACT:

Flibanserin is the initial pharmaceutical treatment for hypoactive sexual desire disorder (HSDD). The analysis of urine samples plays a crucial role in the quantitation of flibanserin since a portion of flibanserin is excreted unchanged in the urine. An analytical method was proposed to quantify flibanserin in artificial urine samples (as model matrices). The integration of the spray‐assisted fine droplet formation‐liquid phase microextraction (SFDF‐LPME) method and gas chromatography–mass spectrometry (GC–MS) system was performed for the first time to improve the sensitivity of the GC–MS system for flibanserin. Several parameters, including spraying cycle, extraction solvent type, mixing type and period, and sample volume, were systematically optimized to enhance the signal‐to‐noise ratio (S/N) of the analyte. After determining the optimal conditions, the analytical performance measurements of the system were figured out. The limit of detection (LOD), the limit of quantification (LOQ), and coefficient of determination (R 2 ) values were 6.91, 23.05 μg kg −1 , and 0.9989, respectively. Recovery experiments were performed in artificial urine samples within the specified linear working range of 33.15–505.66 μg kg −1 . The SFDF–LPME–GC–MS method was efficiently applied to artificial urine samples by computing the matrix‐matching calibration strategy, with percentage recovery values ranging from 90.0% to 105.9%.

01 Jan 2026·Journal of Minimally Invasive Gynecology

Female Sexual Desire, Arousal, and Orgasmic Dysfunctions: A Systematic Review and Meta-Analysis of Treatment Options

Review

Author: Hacker, Michele R ; Winkelman, William D ; Reyes-Gonzalez, Daniela ; Fladger, Anne ; Toledo, Rafaela Germano ; Bergeron, Sophie ; Anand, Mallika

OBJECTIVE:

To conduct a systematic review and meta-analysis of treatments for female sexual desire, arousal, and orgasmic dysfunction in patients without sexual pain conditions.

DATA SOURCE:

MEDLINE, Embase, Web of Science, Cochrane Library, PsycINFO, and ClinicalTrials.gov.

METHODS OF STUDY SELECTION:

Following the initial search in December 2024, a total of 8994 abstracts were screened, 278 full-text articles were reviewed, and 36 studies met criteria for data abstraction including a patient population with female sexual dysfunction (FSD) of desire, arousal, and/or orgasm (DAO) and outcome measures including the Female Sexual Function Index (FSFI), its DAO subscales, and the Female Sexual Distress Scale (FSDS). Studies including patients with sexual pain conditions were excluded. Two reviewers independently conducted each phase.

TABULATION, INTEGRATION, AND RESULTS:

Of the 36 studies, 26 were RCTs and 10 were single-arm trials. Ten studies evaluated cognitive behavioral therapy (CBT), 24 investigated medication therapy, and 2 investigated devices. Meta-analyses were conducted for mindfulness-based CBT, flibanserin, and bremelanotide. Mindfulness-based CBT significantly improved total FSFI and subscales of desire, arousal, and orgasm. Conversely, flibanserin improved total FSFI and desire while bremelanotide improved total FSFI and its desire and arousal subscales. No studies directly compared CBT to pharmacotherapy.

CONCLUSION:

In this systematic review of treatments of females with sexual DAO dysfunctions without pain, we found that CBT improves DAO; flibanserin improves desire; and bremelanotide improves both desire and arousal; and all 3 treatments reduce distress. Our findings align with previous literature and expand upon it to include multiple treatment modalities. This broader perspective offers a starting point for clinicians, including gynecologists, who frequently serve as the first point of care for FSD. Conclusions regarding most other treatments could not be drawn due to limited numbers of studies of FSD excluding pain, heterogeneous terminology for DAO disorders, and varying outcome measures across studies.

01 Dec 2025·Journal of Minimally Invasive Gynecology

Strategies for Treating Sexual Health Concerns After Breast and Gynecologic Cancer

Article

Author: Rojas, Kristin E ; Curran, Melissa ; Mihulka, Olivia ; Narasimhan, Raksha M ; Moore, Jessica F

OBJECTIVE:

Sexual dysfunction is a common but underrecognized sequelae of breast and gynecologic cancer treatment. Many patients experience symptoms of genitourinary syndrome of menopause, including vaginal dryness, dyspareunia, and diminished sexual desire. Addressing these challenges requires a comprehensive, evidence-based approach to management.

DATA SOURCES:

A comprehensive literature search was conducted using PubMed, Google Scholar, and Scopus to identify peer-reviewed studies published within the last 30 years. The search incorporated Medical Subject Headings and keywords related to sexual dysfunction and cancer survivorship, including terms such as "sexual dysfunction," "dyspareunia," "vaginal dryness," "vaginal hormone therapy," "breast cancer survivors," and "low desire."

METHODS OF STUDY SELECTION:

Studies were included if they examined sexual dysfunction in cancer patients or survivors, were published in English, and addressed either physiological or psychological aspects of sexual health. Articles were excluded if they lacked methodological rigor. An initial screening of titles and abstracts was followed by full-text review to determine relevance and inclusion.

TABULATION:

Findings were synthesized using thematic analysis, with studies grouped by cancer type, treatment modality, and impact on sexual function. Although no formal quality assessment tool was applied, emphasis was placed on high-impact studies and comprehensive reviews published in reputable journals.

INTEGRATION AND RESULTS:

Effective management of genitourinary syndrome of menopause includes nonhormonal options such as minimizing irritants, vaginal moisturizers, lubricants, the use of dilators, and pelvic floor therapies. Local hormonal therapies may offer relief for select patients depending on the hormone sensitivity of their cancer diagnosis. For low sexual desire, psychological and pharmacological agents such as bremelanotide and flibanserin have demonstrated efficacy. Vaginal lasers and compounded hormones pose significant risks to these patient populations and should be avoided. Multidisciplinary approaches, incorporating gynecologic, psychological, and oncologic expertise, are essential for optimizing patient outcomes.

CONCLUSION:

Sexual dysfunction following breast and gynecologic cancer requires individualized, multimodal management. A combination of nonhormonal and hormonal therapies, behavioral interventions, and emerging pharmacologic treatments offers promising avenues for improving sexual health and overall quality of life in survivors. Future research should focus on the effects of specific cancer therapies on sexual health, investigate the role of biological markers and dysfunction, and refine more personalized approaches to care.

News (Medical) associated with Flibanserin

09 Jan 2026

·www.einpresswire.com

Analysis of WAC Price Changes Shows Modest Increases During Peak Adjustment Period

FAYETTEVILLE, NY, UNITED STATES, January 9, 2026 / EINPresswire.com / -- January is traditionally a peak period for pharmaceutical list price adjustments. The AnalySource team analyzed Wholesale Acquisition Cost (WAC) package pricing changes for all single-source prescription products with effective dates surrounding the new year, spanning December 1, 2025 through February 28, 2026. Overall, the analysis shows that most price changes were modest, though a limited number of notable outliers were observed. The analysis encompassed 1,902 National Drug Codes (NDCs) representing all identified single-source products with WAC package pricing changes during the analysis period. Only a small subset exhibited material pricing movement, with 11 drugs, some with various formulations, reporting WAC package price decreases and 31 products recording WAC package price increases of 10% or greater. These findings underscore that large price movements remain the exception rather than the norm, even during peak annual pricing cycles. Several significant outliers stood out in the data. Sandoz’s CIMERLI reported an 85.29% decrease in WAC package price, representing the largest reduction observed during the period. The largest WAC package price increase in the dataset was reported by PAI Holdings for TRIHEXYPHENIDYL (+480%). In addition, the most extreme WAC package price increases were highly concentrated within a small number of manufacturers, with Hospira/Pfizer accounting for the majority of increases exceeding 300%, including Verapamil HCl (+377%), Lorazepam (+346%), Naloxone HCl (+334%), and Hydromorphone HCl (+318%). These products are commonly used in hospital and acute care settings, where pricing dynamics may differ from those of outpatient or retail-dispensed therapies. Other notable movements included Sprout Pharmaceuticals, which reported a 110.64% increase for ADDYI, a branded product indicated for sexual function disorders. Novo Nordisk implemented substantial price decreases across multiple insulin products, including Fiasp and Tresiba presentations, reflecting a coordinated portfolio-level pricing adjustment rather than isolated product changes. Several manufacturers exhibited mixed pricing strategies within their portfolios. Boehringer Ingelheim reported modest price increases for products such as Ofev, Pradaxa, and Gilotrif while simultaneously implementing price decreases of approximately 44% for several other products. Pfizer reported both significant price increases across select hospital and specialty products and a price decrease for Xeljanz, a therapy used in inflammatory conditions. Outside of these exceptions, most manufacturers reported modest WAC package price increases in the range of 2% to 6%, consistent with historical annual pricing patterns. Across therapeutic areas, these adjustments align with routine pricing activity that may reflect product lifecycle stage, competitive dynamics, manufacturing considerations, and regulatory developments. While additional list price adjustments are expected later in the pricing cycle, early indications suggest that the majority of products will continue to reflect modest pricing changes, with large increases and decreases remaining relatively limited. The AnalySource team will continue to monitor these developments closely and will provide further updates as additional information becomes available. Daniel Miccio DMD America, Inc. +1 315-400-2289 email us here Visit us on social media: LinkedIn Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

Clinical ResultFinancial Statement

08 Jan 2026

·www.prnewswire.com

PHIL and Sprout Pharmaceuticals Expand Their Affordable Direct-to-Patient Access Program for Addyi(flibanserin)

PHIL expands direct-to-patient access to Addyi for as low as $40 per year with commercial insurance coverage or $149 per month cash whether accessed through telehealth or a doctor's office. SCOTTSDALE, Ariz., Jan. 8, 2026 /PRNewswire/ -- PHIL, the technology-powered patient access platform designed to help patients get easy and affordable access to their prescribed medications, and Sprout Pharmaceuticals, today announced that they have expanded Sprout's direct-to-patient program for Addyi (flibanserin). Addyi has recently received an expanded indication from the FDA and is now approved to treat hypoactive sexual desire disorder (HSDD) in women less than 65 years of age. Addyi, an HSDD therapy developed by Sprout Pharmaceuticals, is made for women experiencing distressing low desire and is the only FDA-approved pill proven to increase a woman's sex drive in both premenopausal and postmenopausal women. The goal of the expanded direct-to-patient program is to help patients prescribed Addyi have a more accessible, convenient, and affordable path to start and remain on therapy. Addyi's robust direct-to-patient solution powered by PHIL, offers seamless medication access with telemedicine services, the lowest out-of-pocket cost for commercially insured and cash-pay patients, and free home delivery across the U.S. Through PHILRx, Addyi may cost as low as $40 per year with commercial insurance coverage or $149 per month for cash pay. All patients receive free home delivery. Healthcare providers can send prescriptions to PHILRx through their EMR. For more information, see phil.us/addyi. "The best patient experience begins with affordable access. We're incredibly proud of our partnership with PHIL because it ensures that women prescribed Addyi, whether through an in-office visit or telehealth, can obtain the medication at the right price. Today 80% of Addyi patients pay under $100 per month through PHILRx, with more than half paying $40 annually with insurance coverage. This program delivers on exactly what we set out to do, it removes longstanding barriers to access in women's sexual health," said Cindy Eckert, CEO of Sprout Pharmaceuticals. Whether prescriptions come from an in-office doctor or a telehealth provider, PHIL helps make the prescription experience simple, convenient, and affordable. Patients prescribed Addyi can receive their prescription on time and at their doorstep — with affordability support designed to help patients pay the lowest out-of-pocket cost available. Additionally, PHIL offers proactive refill support to help patients stay adherent to therapy. "Patients deserve a medication access experience that's as modern as the science," said Deepak Thomas, Founder & CEO of PHIL. "When a clinician decides Addyi is appropriate, PHIL helps remove barriers commonly found in traditional access challenges, with an affordability-first approach that's built around the patient." About PHIL/PHILRx PHIL is on a mission to improve patients' lives through innovative technology and dedicated support. The PHIL platform is designed to help more patients start and stay on therapy, quickly, easily and affordably. Learn more at . About Sprout Pharmaceuticals Sprout Pharmaceuticals is leading a revolution in women's health, pioneering innovative treatments that address long-overlooked needs. With the launch of Addyi, the first and only FDA-approved pill to treat low sexual desire (HSDD), Sprout helped shift the conversation around women's sexual wellness. The company remains committed to advancing science, expanding access, and advocating for the care women deserve. See full prescribing Information, including Boxed Warning regarding severe low blood pressure and fainting in certain settings at addyi.com/pi Media Contact: Alyssa Newby PANBlast for PHIL [email protected] SOURCE Phil 21% more press release views with Request a Demo

Drug Approval

19 Dec 2025

·www.prnewswire.com

Weekly Recap: 13 Health Press Releases You Need to See

A roundup of the most newsworthy healthcare press releases from PR Newswire this week, including a growing alliance to curtail foodborne illnesses, and resources to help people quit nicotine and tobacco for good. NEW YORK, Dec. 19, 2025 /PRNewswire/ -- With thousands of press releases published each week, it can be difficult to keep up with everything on PR Newswire. To help healthcare journalists and consumers stay on top of the week's most newsworthy and popular releases, here's a recap of some major stories from the week that shouldn't be missed. The list below includes the headline (with a link to the full text) and an excerpt from each story. Click on the press release headlines to access accompanying multimedia assets that are available for download. Continue Reading PR Newswire Weekly Health Press Release Roundup, Dec. 15-19, 2025. ADEL Signs $1.04 Billion Global License Agreement with Sanofi for ADEL-Y01, a Novel Investigational Alzheimer's Disease Therapy ADEL will receive a non-refundable upfront payment of $80 million and is eligible to receive additional payments contingent upon the achievement of specified development and commercial milestones. Additionally, ADEL is entitled to receive tiered royalties on net sales ranging up to double-digit percentages. Nonprofits, Closegap and Koko, Partner to Scale Evidence-Based Interventions in K-12 Schools The partnership integrates Koko's clinical-grade, peer-reviewed support tools directly into Closegap's daily check-ins, allowing schools to instantly respond from detecting a student need to providing an evidence-based intervention. Historic First in Women's Sexual Health: FDA Grants Approval for Addyi® (flibanserin) in Postmenopausal Women Addyi, the first and only FDA-approved pill clinically proven to treat frustrating low sexual desire in women, is now approved for use in women who have gone through menopause. Abbott's Amplatzer Piccolo™ Delivery System Receives FDA Clearance and CE Mark to Optimize Procedures for Premature Babies With a Hole in the Heart It's the first and only delivery system designed specifically for premature infants with a patent ductus arteriosus (PDA), a life-threatening opening in their heart. The new delivery system enables precise placement of Abbott's Amplatzer Piccolo Occluder in the tiniest babies. Paralyzed Veterans of America Issues Statement in Response to the Department of Veterans Affairs' Reorganization of VHA "Paralyzed Veterans of America has long raised concerns about how administrative bloat has hindered health care decision-making and made it difficult for VHA to hire the staff needed to deliver health care services more effectively. We believe reorganizing to eliminate, or at least significantly reduce, these unnecessary barriers is long overdue. We applaud the Secretary and his team for taking steps in this direction and look forward to seeing how this reorganization will improve catastrophically disabled veterans' care." Link Cell Therapies Launches with Vision of Advancing CAR-T Therapies in Solid and Liquid Tumors Link's proprietary logic-gating technologies allow for safe targeting of multiple antigens that are co-expressed on cancer cells but do not overlap or only minimally overlap in their normal healthy tissue expression. This platform enables the creation of next-generation CAR-T therapeutics for solid and liquid cancers built upon an entirely new landscape of "clean" target pairs. Support for Parents with Infants at Pediatric Check-Ups Leads to Better Reading and Math Skills in Elementary School This is the finding of a new study, led by researchers at NYU Grossman School of Medicine, New York University, and the University of Pittsburgh, which evaluated the effects of a comprehensive model to support parenting. Five Leading Organizations Join the Alliance to Stop Foodborne Illness Amazon, Amerisan, the Meat Institute, Mérieux NutriSciences, and Yum! Brands join the collaborative effort to prevent foodborne illness and protect consumers. The Alliance's unique model brings together industry leaders, consumers, academics, and regulatory stakeholders who recognize that food safety is a shared responsibility. Kick the Nic in 2026: American Lung Association Offers Support to Help People Quit All Nicotine and Tobacco Products for Good Currently, 16.4% of adults in the U.S. use at least one tobacco or nicotine product such as cigarettes, e-cigarettes or nicotine pouches. Nicotine is extremely addictive, so the American Lung Association is offering free resources and support to help people quit tobacco and nicotine products for good. Enginprime Medical Inc Announces First-in-Human Study of Its Leading OpusOne™ pVAD This milestone marks the first clinical evaluation of the device's safety and performance in patients. PVAD supports the cardiac output via a percutaneously implanted pump, reduces the load of left ventricle, relieves heart failure symptoms, and bridges to transplantation or recovery. Introducing Hundred Health: The First Truly Integrated Health Platform That Turns Data Into Personalized 100-Day Action Plans Priced at $499 annually, Hundred provides 160+ lab tests per year across two visits either in-lab at 5,000 partner facilities or in-home phlebotomy at an additional cost, along with clear interpretation of results and a personalized 100-day protocol — a level of precision once reserved for the ultra-wealthy. Hundred is making evidence-based, personalized care truly accessible. Protect Your Loved Ones on the Road This Holiday Season This year, the National Safety Council estimates 431 traffic fatalities during the Christmas holiday period and 429 during New Year's – tragedies that would leave hundreds of families and friends facing the holidays with an empty seat at the table. Medivis First to Receive FDA Clearance for Augmented Reality Navigation in Neurosurgery By using augmented reality to spatially map patient imaging within the operative field, the Medivis platform gives surgeons a clear, real-time view of critical anatomy and planned trajectories. This approach can support faster, more confident decision-making during cranial procedures while minimizing workflow disruption and reducing dependence on external monitors. For more news like this, check out all of the latest health-related releases from PR Newswire. Do you have a health press release to distribute? Sign up with PR Newswire to share your story with the audiences who matter most. Helping Journalists Stay Up to Date on Industry News These are just a few of the recent press releases that consumers and the media should know about. To be notified of releases relevant to their coverage area, journalists can set up a custom newsfeed with PR Newswire for Journalists. Once they're signed up, reporters, bloggers, and freelancers have access to the following free features: Customization: Users can create customized newsfeeds that will deliver relevant news right to their inbox. Newsfeed results can be targeted by keywords, industry, subject, geography, and more. Photos and Videos: Thousands of multimedia assets are available to download and include in a journalist or blogger's next story. Subject Matter Experts: Journalists will have access to ProfNet, a database of industry experts to connect with as sources or for quotes in their articles. Related Resources: Our journalist- and blogger-focused blog, Beyond Bylines, features regular media news roundups, writing tips, upcoming events, and more. About PR Newswire PR Newswire is the industry's leading press release distribution partner with an unparalleled global reach of more than 440,000 newsrooms, websites, direct feeds, journalists and influencers and is available in more than 170 countries and 40 languages. From our award-winning Content Services offerings, integrated media newsroom and microsite products, Investor Relations suite of services, paid placement and social sharing tools, PR Newswire has a comprehensive catalog of solutions to solve the modern-day challenges PR and communications teams face. For 70 years, PR Newswire has been the preferred destination for brands to share their most important news stories across the world. For questions, contact the team at [email protected]. SOURCE PR Newswire 21% more press release views with Request a Demo

Drug ApprovalLicense out/in

100 Deals associated with Flibanserin

External Link

KEGG	Wiki	ATC	Drug Bank
D02577	Flibanserin	G02CX02	DB04908

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Sexual Dysfunctions, Psychological	United States	Sprout Pharmaceuticals, Inc.	18 Aug 2015

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Decreased libido	NDA/BLA	United States	Sprout Pharmaceuticals, Inc.	-
Depressive Disorder	Phase 3	United States	Sprout Pharmaceuticals, Inc.	01 Jan 2010

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT02770768 (CTgov)	Not Applicable	Sexual Dysfunctions, Psychological	57	Flibanserin (Flibanserin)	kojbgnttbh(tozltpfugl) = zygriedppc vogmxwmwtr (rttdgdnaqr, qlcrdgausy - uidmmyggrf) View more	-	16 May 2024
				Placebo (Placebo)	kojbgnttbh(tozltpfugl) = fjyuhbibum vogmxwmwtr (rttdgdnaqr, rjbmzfetyb - pcucnhlvhf) View more
NCT03707340 (ASCO2023)	Not Applicable	Breast Cancer Adjuvant	37	Flibanserin 100mg	unjawucman(vkeaqcyruo) = pgkagumdvg axcfmjagkz (fautfzwdsb )	Positive	31 May 2023
NCT01057901 (PLUMERIA, Pubmed \| J Sex Med) Manual	Phase 3	Sexual Dysfunctions, Psychological	745	Flibanserin	zqwxuolajo(udaomlmmdn): P-Value = 0.011 View more	Positive	01 Jun 2017
				Placebo
AUA2017	Not Applicable	-	-	Flibanserin	kgujfypfap(bsctizrdhr) = No serious adverse events were noted elnbnyhkez (ntbijatemb )	Positive	01 Apr 2017
NCT01040208 (CTgov)	Phase 3	Sexual Dysfunctions, Psychological \| Depressive Disorder	111	flibanserin 50 mg to 100 mg qhs (Flibanserin 50 mg to 100 mg Qhs)	qdbchzfvnm = syhmdoixtz rdjreohvur (hvcqrotspd, uyadptnzas - ovggbulblf) View more	-	24 Aug 2016
				flibanserin 100 mg qhs (Flibanserin 100 mg Qhs)	qdbchzfvnm = jpqjsrgjrp rdjreohvur (hvcqrotspd, xfhjurcmpt - yzacqsxqeo) View more
NCT00360243 (CTgov)	Phase 3	Sexual Dysfunctions, Psychological \| Decreased libido	1,385	flibanserin (Flibanserin 25 mg b.i.d)	jmqpxigwpu(dqkpvzumud) = kdwhtfijmn nvvgwganfs (qowrlvldsh, 3.4) View more	-	27 Jun 2016
				flibanserin (Flibanserin 50mg Qhs)	jmqpxigwpu(dqkpvzumud) = pcndqpnybs nvvgwganfs (qowrlvldsh, 4.2) View more
NCT00360529 (CTgov)	Phase 3	Sexual Dysfunctions, Psychological \| Decreased libido	880	flibanserin	fqvisdsxmm(rnvrfiutyv) = nnwxamlnvu utsrlfkqge (jhucgjmcou, 3.4) View more	-	27 Jun 2016
NCT00360555 (CTgov)	Phase 3	Sexual Dysfunctions, Psychological	1,584	flibanserin	prptcfjsoz(cnegvacxgt) = nwupvlfyus koafqwfxnd (noeahztriu, 3.4) View more	-	27 Jun 2016
NCT00601367 (CTgov)	Phase 3	Sexual Dysfunctions, Psychological	480	flibanserin flexible dose	wjzuuvpzxd = sdnrvafxzt hgxefwfajo (kmurxphecn, xeuiuljjen - xdookxmiav) View more	-	20 Jun 2014
NCT01057901 (PLUMERIA, CTgov)	Phase 3	Sexual Dysfunctions, Psychological	748	Flibanserin (Flibanserin 100 mg)	eqvilhlxts(cynihsnfqc) = xrfnqenlrg dizxzihaon (lolgoknofb, 3.3) View more	-	17 Jun 2014
				Placebo (Placebo)	eqvilhlxts(cynihsnfqc) = qkbxjekosg dizxzihaon (lolgoknofb, 2.9) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis